Consolidated Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7582766

Concept 2022-01-01 to
2022-09-30
As at
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
As at
2019-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-270,904,000 JPY
144,914,000 JPY
-327,492,000 JPY
Depreciation
18,496,000 JPY
32,894,000 JPY
Interest expenses
5,236,000 JPY
5,934,000 JPY
Foreign exchange losses (gains)
1,158,000 JPY
-639,000 JPY
Decrease (increase) in trade receivables
-37,701,000 JPY
-7,645,000 JPY
Subtotal
84,396,000 JPY
-349,248,000 JPY
Decrease (increase) in inventories
-38,527,000 JPY
20,858,000 JPY
Income taxes paid
-2,009,000 JPY
-2,009,000 JPY
Increase (decrease) in trade payables
7,733,000 JPY
-56,418,000 JPY
Net cash provided by (used in) operating activities
161,537,000 JPY
-294,001,000 JPY
Other, net
2,689,000 JPY
1,404,000 JPY
Interest paid
-3,970,000 JPY
-5,757,000 JPY
Cash flows from investing activities
Payments into time deposits
-100,000,000 JPY
JPY
Proceeds from withdrawal of time deposits
100,000,000 JPY
JPY
Purchase of property, plant and equipment
JPY
-264,000 JPY
Net cash provided by (used in) investing activities
-50,583,000 JPY
-264,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
207,750,000 JPY
100,000,000 JPY
Proceeds from long-term borrowings
JPY
469,787,000 JPY
Net increase (decrease) in short-term borrowings
69,201,000 JPY
-9,611,000 JPY
Repayments of long-term borrowings
-24,361,000 JPY
-13,825,000 JPY
Net cash provided by (used in) financing activities
229,206,000 JPY
488,905,000 JPY
Net increase (decrease) in cash and cash equivalents
340,161,000 JPY
194,639,000 JPY
Cash and cash equivalents
1,613,040,000 JPY
1,272,879,000 JPY
1,078,239,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.